These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 33442231)

  • 1. Biologic Therapies for Giant Cell Arteritis.
    Harrington R; Al Nokhatha SA; Conway R
    Biologics; 2021; 15():17-29. PubMed ID: 33442231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of biologics in the treatment of giant cell arteritis.
    González-Gay MA; Pina T; Prieto-Peña D; Calderon-Goercke M; Blanco R; Castañeda S
    Expert Opin Biol Ther; 2019 Jan; 19(1):65-72. PubMed ID: 30513026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature.
    Loricera J; Tofade T; Prieto-Peña D; Romero-Yuste S; de Miguel E; Riveros-Frutos A; Ferraz-Amaro I; Labrador E; Maiz O; Becerra E; Narváez J; Galíndez-Agirregoikoa E; González-Fernández I; Urruticoechea-Arana A; Ramos-Calvo Á; López-Gutiérrez F; Castañeda S; Unizony S; Blanco R
    Arthritis Res Ther; 2024 Jun; 26(1):116. PubMed ID: 38840219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Giant cell arteritis: pathogenic mechanisms and new potential therapeutic targets.
    Koster MJ; Warrington KJ
    BMC Rheumatol; 2017; 1():2. PubMed ID: 30886946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current advances in the treatment of giant cell arteritis: the role of biologics.
    Low C; Conway R
    Ther Adv Musculoskelet Dis; 2019; 11():1759720X19827222. PubMed ID: 30800174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Giant cell arteritis: what is new in the preclinical and early clinical development pipeline?
    Harkins P; Conway R
    Expert Opin Investig Drugs; 2022 Sep; 31(9):921-932. PubMed ID: 34106030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic Therapy for the Treatment of Giant Cell Arteritis.
    Ostrowski RA; Bussey MR; Tehrani R; Jay W
    Neuroophthalmology; 2014; 38(3):107-112. PubMed ID: 27928284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and emerging diagnosis tools and therapeutics for giant cell arteritis.
    González-Gay MA; Pina T; Prieto-Peña D; Calderon-Goercke M; Blanco R; Castañeda S
    Expert Rev Clin Immunol; 2018 Jul; 14(7):593-605. PubMed ID: 29877748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies.
    Cid MC; Ríos-Garcés R; Terrades-García N; Espígol-Frigolé G
    Rheumatology (Oxford); 2020 May; 59(Suppl 3):iii17-iii27. PubMed ID: 32348525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of giant cell arteritis.
    González-Gay MÁ; Pina T; Prieto-Peña D; Calderon-Goercke M; Gualillo O; Castañeda S
    Biochem Pharmacol; 2019 Jul; 165():230-239. PubMed ID: 31034796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological treatments in giant cell arteritis & Takayasu arteritis.
    Samson M; Espígol-Frigolé G; Terrades-García N; Prieto-González S; Corbera-Bellalta M; Alba-Rovira R; Hernández-Rodríguez J; Audia S; Bonnotte B; Cid MC
    Eur J Intern Med; 2018 Apr; 50():12-19. PubMed ID: 29146018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Giant Cell Arteritis (GCA).
    Régent A; Mouthon L
    J Clin Med; 2022 Mar; 11(7):. PubMed ID: 35407411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic treatment of large-vessel vasculitides.
    Schäfer VS; Zwerina J
    Curr Opin Rheumatol; 2012 Jan; 24(1):31-7. PubMed ID: 22089099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [From pathogenesis of giant cell arteritis to new therapeutic targets].
    Samson M; Bonnotte B
    Rev Med Interne; 2017 Oct; 38(10):670-678. PubMed ID: 28800947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances and challenges in management of large vessel vasculitis.
    Chu CQ
    Rheumatol Immunol Res; 2023 Dec; 4(4):188-195. PubMed ID: 38125643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the Treatment of Giant Cell Arteritis.
    Castañeda S; Prieto-Peña D; Vicente-Rabaneda EF; Triguero-Martínez A; Roy-Vallejo E; Atienza-Mateo B; Blanco R; González-Gay MA
    J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of large-vessel vasculitis.
    Salvarani C; Hatemi G
    Curr Opin Rheumatol; 2019 Jan; 31(1):25-31. PubMed ID: 30461542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis.
    Koster MJ; Matteson EL; Warrington KJ
    Curr Opin Rheumatol; 2016 May; 28(3):211-7. PubMed ID: 26885650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on the management of giant cell arteritis.
    Roberts J; Clifford A
    Ther Adv Chronic Dis; 2017 Apr; 8(4-5):69-79. PubMed ID: 28491267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways.
    Espígol-Frigolé G; Planas-Rigol E; Lozano E; Corbera-Bellalta M; Terrades-García N; Prieto-González S; García-Martínez A; Hernández-Rodríguez J; Grau JM; Cid MC
    Front Immunol; 2018; 9():809. PubMed ID: 29731755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.